Trinity Biotech (Trinity Biotech) Additional Paid-In Capital : $46.62 Mil(As of Sep. 2023)

View and export this data going back to 1995. Start your Free Trial

What is Trinity Biotech Additional Paid-In Capital?

Trinity Biotech's quarterly additional paid-in capital increased from Mar. 2023 ($46.53 Mil) to Jun. 2023 ($46.62 Mil) but then stayed the same from Jun. 2023 ($46.62 Mil) to Sep. 2023 ($46.62 Mil).

Trinity Biotech's annual additional paid-in capital stayed the same from Dec. 2020 ($16.19 Mil) to Dec. 2021 ($16.19 Mil) but then increased from Dec. 2021 ($16.19 Mil) to Dec. 2022 ($46.46 Mil).

Trinity Biotech Additional Paid-In Capital Historical Data

The historical data trend for Trinity Biotech's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Trinity Biotech Additional Paid-In Capital Chart

Trinity Biotech Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Additional Paid-In Capital

Get a 7-Day Free Trial

16.19

46.46

Trinity Biotech Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Additional Paid-In Capital	Get a 7-Day Free Trial															53.30	46.46	46.53	46.62	46.62

Trinity Biotech Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Trinity Biotech Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Trinity Biotech's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Trinity Biotech (Trinity Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Trinity Biotech PLC (NAS:TRIB) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

TRBA:Germany

Address

IDA Business Park, Bray, County Wicklow, Dublin, IRL, A98 H5C8

Website

https://www.trinitybiotech.com

Trinity Biotech PLC is in the business of development, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point of care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Premier, Immublot, EZ, Capita, and others. Geographically, it has two segments namely the Americas, and Rest of World - Ireland of which it derives a majority of its revenues from the Americas segment.